OSE Immunotherapeutics SA (FRA:6OP)

Market Cap	75.64M -47.7%
Revenue (ttm)	2.69M -93.7%
Net Income	-37.69M
EPS	-1.69
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.164
Previous Close	3.156
Day's Range	3.164 - 3.164
52-Week Range	2.856 - 7.165
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 28, 2026

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company’s products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical tria...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6OP

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error